Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 16946304

Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG).

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Blood
Publication date
2006 Dec 15
First author
Forstpointner R

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Nat Clin Pract Oncol. 2007 Jul;4(7):402-3. doi: 10.1038/ncponc0842.
    note
    Source null
    related pmid
    17519919
    relationship
    Comment in

Authors and identifiers

  1. name
    Forstpointner R
    type
    Author
  2. name
    Unterhalt M
    type
    Author
  3. name
    Dreyling M
    type
    Author
  4. name
    Böck HP
    type
    Author
  5. name
    Repp R
    type
    Author
  6. name
    Wandt H
    type
    Author
  7. name
    Pott C
    type
    Author
  8. name
    Seymour JF
    type
    Author
  9. name
    Metzner B
    type
    Author
  10. name
    Hänel A
    type
    Author
  11. name
    Lehmann T
    type
    Author
  12. name
    Hartmann F
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Forstpointner R
    type
    Author
  2. name
    Unterhalt M
    type
    Author
  3. name
    Dreyling M
    type
    Author
  4. name
    Böck HP
    type
    Author
  5. name
    Repp R
    type
    Author
  6. name
    Wandt H
    type
    Author
  7. name
    Pott C
    type
    Author
  8. name
    Seymour JF
    type
    Author
  9. name
    Metzner B
    type
    Author
  10. name
    Hänel A
    type
    Author
  11. name
    Lehmann T
    type
    Author
  12. name
    Hartmann F
    type
    Author
bibliography ids
  1. nci-bib-8e346026251082b581475fcc
book metadata
content sha256
314c14ea35be3f20ae268df9ff2c5d6fe9b4204aa9d3361421d3c89e3d86e902
document type
citation
dois
  1. 10.1182/blood-2006-04-016725
electronic publication date
display
2006 Aug 31
precision
day
year
2006
evidence scope
bibliographic_metadata_only
id
pubmed:16946304
immutable id
pubmed:16946304@314c14ea35be3f20ae268df9ff2c5d6fe9b4204aa9d3361421d3c89e3d86e902
journal
abbreviation
Blood
issn electronic
Source null
issn print
0006-4971
issue
13
name
Blood
nlm unique id
7603509
pages
4003-8
volume
108
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Nat Clin Pract Oncol. 2007 Jul;4(7):402-3. doi: 10.1038/ncponc0842.
    note
    Source null
    related pmid
    17519919
    relationship
    Comment in
outcomes validated
false
pmid
16946304
provenance
batch id
2c499a3b9f4867a74c49
provider
NCBI PubMed ESummary
record sha256
a054861f955db61b1da6a479b1c277fa9bf9662475d271d6db7a248d1d3b7bb7
response sha256
3b299651c5c5270455877b65b6e5acff71ad5f85103b7f9582efe63c52588326
retrieved at
2026-09-09T23:46:08.887541+00:00
publication date
display
2006 Dec 15
precision
day
year
2006
publication types
  1. Clinical Trial, Phase II
  2. Comparative Study
  3. Journal Article
  4. Multicenter Study
  5. Randomized Controlled Trial
  6. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/16946304/
title
Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG).

Preserved source evidence · Not medical advice